はしか(Measles):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Measles - Pipeline Review, H1 2015
◆商品コード:GMDHC6416IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年3月31日
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるはしか(Measles)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・はしか(Measles)の概要
・はしか(Measles)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・はしか(Measles)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・はしか(Measles)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・はしか(Measles)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Measles – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Measles – Pipeline Review, H1 2015’, provides an overview of the Measles’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Measles
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Measles and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Measles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Measles pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Measles
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Measles pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Measles Overview 8
Therapeutics Development 9
Pipeline Products for Measles – Overview 9
Pipeline Products for Measles – Comparative Analysis 10
Measles – Therapeutics under Development by Companies 11
Measles – Therapeutics under Investigation by Universities/Institutes 12
Measles – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Measles – Products under Development by Companies 17
Measles – Products under Investigation by Universities/Institutes 18
Measles – Companies Involved in Therapeutics Development 19
Beijing Tiantan Biological Products Co., Ltd. 19
Biological E. Limited 20
China National Pharmaceutical Group Corporation 21
GlaxoSmithKline plc 22
Prometheon Pharma, LLC 23
Serum Institute of India Limited 24
Universal Stabilization Technologies, Inc. 25
Vical Incorporated 26
Zydus Cadila Healthcare Limited 27
Measles – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(measles [schwarz strain] + mumps [RIT 4385 strain] + rubella [wistar RA 27/3 strain])vaccine – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AS-136A – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cell Therapy for Measles, Mumps and Rubella – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ERDRP-0519 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
measles + mumps + rubella + varicella vaccine – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
measles + mumps + rubella + varicella vaccine – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
measles + mumps + rubella vaccine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
measles + mumps + rubella vaccine – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
measles + rubella vaccine – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
measles + rubella vaccine – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
measles + rubella vaccine – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
measles [edmonston - zagreb strain] vaccine – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
measles vaccine – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
measles vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
measles vaccine – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
measles vaccine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Measles – Recent Pipeline Updates 54
Measles – Dormant Projects 55
Measles – Product Development Milestones 56
Featured News & Press Releases 56
Nov 24, 2014: Powdered Measles Vaccine Found Safe In Early Clinical Trials 56
Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

[List of Tables]
Number of Products under Development for Measles, H1 2015 9
Number of Products under Development for Measles - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 19
Measles - Pipeline by Biological E. Limited, H1 2015 20
Measles - Pipeline by China National Pharmaceutical Group Corporation, H1 2015 21
Measles - Pipeline by GlaxoSmithKline plc, H1 2015 22
Measles - Pipeline by Prometheon Pharma, LLC, H1 2015 23
Measles - Pipeline by Serum Institute of India Limited, H1 2015 24
Measles - Pipeline by Universal Stabilization Technologies, Inc., H1 2015 25
Measles - Pipeline by Vical Incorporated, H1 2015 26
Measles - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Assessment by Combination Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Measles Therapeutics - Recent Pipeline Updates, H1 2015 54
Measles - Dormant Projects, H1 2015 55

[List of Figures]
Number of Products under Development for Measles, H1 2015 9
Number of Products under Development for Measles - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 28
Assessment by Combination Products, H1 2015 29
Number of Products by Top 10 Targets, H1 2015 30
Number of Products by Stage and Top 10 Targets, H1 2015 31
Number of Products by Top 10 Mechanism of Actions, H1 2015 32
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Top 10 Routes of Administration, H1 2015 34
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35
Number of Products by Top 10 Molecule Types, H1 2015 36
Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

【掲載企業】

Beijing Tiantan Biological Products Co., Ltd.
Biological E. Limited
China National Pharmaceutical Group Corporation
GlaxoSmithKline plc
Prometheon Pharma, LLC
Serum Institute of India Limited
Universal Stabilization Technologies, Inc.
Vical Incorporated
Zydus Cadila Healthcare Limited

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[はしか(Measles):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆